NewYork-Presbyterian, with Columbia University Medical Center and Weill Cornell Medicine, was recognized in the 2016 edition of Becker's Hospital Review’s 100 Hospitals and Health Systems with Great Oncology Programs, featuring hospitals and health systems leading the nation in cancer care.

Dr. Haviva Veler, director of the Pediatric Sleep and Breathing Disorders Center at Weill Cornell Medicine and pediatrician at NewYork-Presbyterian/Phyllis and David Komansky Center for Children’s Health, offers tips to help get kids back on track to receive sufficient rest.

A vaccine developed at Weill Cornell Medicine and NewYork-Presbyterian to blunt the effects of cocaine has advanced to clinical trials for testing in humans. After demonstrating that the vaccine prevented cocaine from reaching the brain in earlier animal studies, investigators are now enrolling active cocaine addicts in a Phase I randomized control study to test how it works in people.

NewYork-Presbyterian, one of the largest and most comprehensive hospitals in the nation, is ranked New York’s No. 1 hospital for the 16th consecutive year, and No. 6 in the United States, according to the U.S. News and World Report annual survey of “Best Hospitals,” published online today. The hospital has been once again included in the prestigious Honor Roll, which recognizes national excellence in multiple specialties.

NewYork-Presbyterian has announced the rollout of NYP OnDemand, a new suite of digital health services designed to improve and expand patient care, while also extending access to the clinical expertise of NewYork-Presbyterian’s physicians to their peers throughout the Hospital’s vast healthcare network. NewYork-Presbyterian is one of the largest, most comprehensive medical institutions in the nation and the only one on this scale to implement an enterprise-wide, comprehensive digital health portfolio.

Dr. Charles G. Drake has joined NewYork-Presbyterian/Columbia University Medical Center (CUMC) as director of genitourinary oncology and associate director for clinical research at the Herbert Irving Comprehensive Cancer Center, effective October 1. A nationally recognized expert in immunotherapy, Professor Drake will also serve as co-director of Columbia’s Cancer Immunotherapy Program and on the faculty of CUMC.

An international study has found that transcatheter cerebral embolic protection (TCEP) is safe, provides effective capture of embolic debris and does not change neurocognitive function for transcatheter aortic valve replacement (TAVR) patients.

Optical coherence tomography (OCT) provides safe and improved guidance for patients undergoing percutaneous coronary intervention to treat coronary artery disease, according to results from the ILLUMIEN III: OPTIMIZE PCI trial. The trial sought to determine whether a novel OCT-based stent sizing strategy would result in a comparable or superior minimal stent area (MSA) as achieved with former stent implant imaging techniques.